Archive
1250 articles, sorted by publication time.
From in-hospital diagnostic tools to health assistants used independently by patients, two scholars propose measuring risk by “decision-making authority,” allowing regulatory intensity to vary with AI’s ability to influence real-world medical choices.
Researchers used mesothelin and NECTIN2, respectively, to recognize cancer cells and deliver the CD3 activation signal and CD28 costimulatory signal to T cells. In vitro results showed that double-positive tumors were more susceptible to killing, but animal safety validation and human trials remain far off.
This prescription medical device integrates tissue containment, powered morcellation, and transvaginal extraction into a single system in an effort to shorten the extraction process for large uteri; however, the median time of four minutes appears only in a company summary, and full clinical data have yet to be disclosed.
This oral candidate targeting Hippo cancer signaling is undergoing first-in-human testing in patients with mesothelioma and other advanced solid tumors. The early results to be presented in October will hinge not only on whether tumor responses occur, but also on safety and usable dose levels.
A 15-person early-stage study in China will test PICX as a single-infusion therapy, exploring whether it can eliminate the ex vivo CAR-T cell manufacturing process; however, the drug target and key technical details have not yet been disclosed, and the current focus remains on dosing and safety.
With no approved vaccine available for Bundibugyo virus, Moderna’s mRNA-1469 candidate has entered human testing for the first time in Canada; this Phase 1 trial is intended not to demonstrate disease-prevention efficacy, but to determine whether it can safely advance to studies in outbreak-affected areas.
Researchers loaded an IL-2 variant designed to preferentially activate anticancer immune cells into Bifidobacterium longum, enabling local release of the drug within tumors. Mouse studies showed that it can enhance multiple treatments, but safety and biological-control hurdles remain before it can be used in humans.
This national initiative aims to connect fragmented clinical, genetic, and molecular data with supercomputing, shortening the time it takes for drugs and diagnostics to reach patients; the real tests will be data quality, privacy, and clinical validation.
A model that scores individual features according to C-TIRADS improved two physicians’ benign-versus-malignant assessments across images of 303 nodules. However, the case set was skewed toward malignancy, and the image-reading process was not fully blinded, leaving key validation gaps before routine clinical use.
A research team identified disease-related signals in overnight brainwave recordings from 100 people and found patient clusters corresponding to cerebrospinal fluid markers. The findings offer clues for noninvasive assessment but cannot yet be used to screen for early-stage disease.
pghi-4 disrupts bacterial cell-wall remodeling, making it easier for vancomycin to reach its target and enhancing its efficacy against multiple clinical isolates and in a mouse sepsis model; however, toxicity, selectivity, dosing, and other hurdles remain before it can be used to treat humans.
Four types of mice exposed to the same carcinogen under identical environmental conditions developed 581 liver tumors that diverged markedly in their speed of formation, driver mutations, and genomic stability. The study highlights how innate genetic differences may reshape the evolutionary selection of cancer, although whether the findings extend to humans remains to be verified.